Rusfertide is a hepcidin mimetic peptide. It is filed in this library under heart & blood, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Rusfertide has an FDA-approved product on the U.S. market, marketed as Mimrylo under application NDA220605.
The current label is held by Takeda Pharmaceuticals America, Inc.
From the FDA label
is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV).Quoted from the FDA-approved prescribing information
The evidence
2 sources on Rusfertide published between 2024 and 2025, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Rusfertide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides